Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Active-controlled, Cross-over Study to Assess the Effect of the Sugar Substitute "ENSO 16" on Glucose Metabolism Parameters in Healthy Subjects

NCT05457400 is registered in ClinicalTrials.gov with Alpha Republic GmbH as lead sponsor.

NCT NCT05457400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05457400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Active-controlled, Cross-over Study to Assess the Effect of the Sugar Substitute "ENSO 16" on Glucose Metabolism Parameters in Healthy Subjects
Lead sponsor
Alpha Republic GmbH
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2022
Completion date
July 29, 2022
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sugar; blood, low